Fortis Health.
Fortis Healthcare Q1 FY27 earnings call: Revenue & Margins
Q1 FY27 earnings call: what management said on revenue, margins and capex.
Guidance rank: #31 of 32 in Healthcare Services
See the sector's top 10 — free with your mobile number.
What the Q1 FY27 call signalled
1 of 3 strong
The short version
Agilus Diagnostics targets double-digit revenue growth of around 12%-13% going forward, driven by new leadership and strengthened ground teams. Fortis Healthcare expects hospital EBITDA margin to reach 25% by FY '28, including ESOP costs, driven by brownfield expansions and operational efficiencies.
From Fortis Health.'s Q1 FY27 earnings-call transcript · updated 25 Aug 2026.
Revenue & Sales Performance
- Agilus Diagnostics targets double-digit revenue growth of around 12%-13% going forward, driven by new leadership and strengthened ground teams.
- The diagnostics business aims to improve operating EBITDA margins to 24%-25%.
- Growth in the oncology division has moderated to about 10%-12% in volume terms, down from earlier 23%-24%, mainly due to chemo drug pricing pressures, but future growth is expected via radiation and surgical oncology expansion.
- Hospital occupancy is improving with expectations to increase by 2-3 percentage points as clinical talent and marketing efforts strengthen.
- Expansion plans include operationalizing 400 additional beds in the current year, especially at flagship FMRI, supporting revenue growth.
2 more points from Fortis Health.'s call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Fortis Health. said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- The company plans a 2,000-bed expansion, with around 50% of EBITDA being consumed by this brownfield growth (Page 14).
- Specific Capex for Proton Therapy in Delhi NCR is under finalization, estimated around INR 252 crores (Page 13).
- Bed expansion is ongoing, with 100 beds operationalized in Q1 and another 400 beds expected to come online in the remaining quarters, including 200 beds at the FMRI flagship hospital (Page 12).
- Radiation oncology equipment installation at Manesar to be completed by November, enabling a comprehensive oncology center (Page 8).
- The company is also investing in technical capabilities like proton therapy, robotic surgery, and new cancer care units (Page 14).
2 more points from Fortis Health.'s call on capex
Create a free account to keep reading this call
Top-ranked in Healthcare Services
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Fortis Health. said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Fortis Health. said on order book & pipeline — free account, 30 seconds.
Fortis Health. — Quarterly revenue & net profit
Q1 FY27 figures are not in this chart yet. Latest shown: Mar 2026 (Q4 FY26). The Q1 FY27 numbers from the filing are in the analysis on this page.
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹2.4K Cr, net profit ₹271 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Fortis Health.'s management said in earlier quarters
Others in Healthcare Services this season
- Aatmaj Health (Q1 FY27)
Revenue for Q1 FY 2026-27: ₹8.13 crore . Key investor presentation takeaways from Aatmaj Healthcare Ltd's Q1 FY27 investor presentation — and how it ranks again
- Asarfi Hospital Ltd (Q1 FY27)
Q1'FY27 consolidated revenue from operations: ₹47.5 Cr, up 32.8% YoY (vs ₹35.7 Cr in Q1'FY26) . Key investor presentation takeaways from Asarfi Hospital Ltd's Q
- KMC Speciality (Q1 FY27)
Q1 FY'27 Revenue from operations: INR 91.8 Cr, up 38% YoY from INR 66.6 Cr in Q1 FY'26. Key concall takeaways from KMC Speciality Hospitals (India) Ltd's Q1…
- 3B Blackbio (Q1 FY27)
Q1 2026-27 revenue from operations: ₹3,205.73 Lakh (including Coris sales of ₹862.83 Lakh) vs ₹1,996.06 Lakh in Q1 2025-26 — YoY growth approx. Key concall…
Potential multibaggers · Q2 FY27
Potential multibaggers in Healthcare Services
on management's own guidance
- Strong growth2
- Strong growth1
- Aster DM Quality Care LtdGood growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Fortis Health. and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Fortis Health. Q1 FY27 results?
Agilus Diagnostics targets double-digit revenue growth of around 12%-13% going forward, driven by new leadership and strengthened ground teams. Fortis Healthcare expects hospital EBITDA margin to reach 25% by FY '28, including ESOP costs, driven by brownfield expansions and operational efficiencies.
What is Fortis Health. share price analysis?
Fortis Health. currently shows a below-average growth signal. The stock trades at a P/E of 64.2 with a market cap of ₹68,482 Cr. Investors should review the full earnings analysis for detailed insights.
Is Fortis Health. planning capital expenditure?
The company plans a 2,000-bed expansion, with around 50% of EBITDA being consumed by this brownfield growth (Page 14).
Keep Fortis Health. on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.